[Granulomatosis with polyangiitis]

Dtsch Med Wochenschr. 2017 Jan;142(1):24-31. doi: 10.1055/s-0042-111610. Epub 2017 Jan 5.
[Article in German]

Abstract

Granulomatosis with polyangiitis (GPA) is a potentially life-threatening, rare disease. The etiology is unknown. GPA is histomorphologically characterized by extravascular necrotizing granulomatous inflammation and a systemic necrotizing vasculitis of small to medium-sized vessels. Clinically, a pulmonary-renal syndrome with pulmonary infiltrates, alveolar hemorrhage and a rapidly progressive glomerulonephritis is seen in about 80% of the cases with generalized disease. GPA is associated with proteinase 3-specific anti-neutrophil cytoplasmic autoantibodies (PR3-ANCA). Treatment is guided by severity of organ involvement and disease activity. Cytostatic immunosuppressants or the monoclonal anti-CD20 antibody rituximab are applied.

MeSH terms

  • Combined Modality Therapy / methods
  • Diagnosis, Differential
  • Evidence-Based Medicine
  • Granulomatosis with Polyangiitis / diagnosis*
  • Granulomatosis with Polyangiitis / therapy*
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunosuppressive Agents / administration & dosage*
  • Rituximab / administration & dosage*
  • Treatment Outcome

Substances

  • Immunologic Factors
  • Immunosuppressive Agents
  • Rituximab